Gene Therapy Biotechs Treating Sanfilippo Syndrome Hit Cash Crunch

Despite promising clinical data and solid regulatory plans, biotech firms hoping to address the unmet need in Sanfilippo Syndrome through gene therapy are facing financial struggles.

Gene Therapies Are Risky Business For Both Developers And Investors • Source: Shutterstock

More from Business

More from Scrip